Abstract
The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of
| Original language | English |
|---|---|
| Pages (from-to) | 1062-1067 |
| Number of pages | 6 |
| Journal | American Journal of Hematology |
| Volume | 88 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2013 |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. / Rambaldi, Alessandro; Boschini, Cristina; Gritti, Giuseppe; Delaini, Federica; Oldani, Elena; Rossi, Andrea; Barbui, Anna Maria; Caracciolo, Daniele; Ladetto, Marco; Gueli, Angela; De Crescenzo, Alberto; Passera, Roberto; Devizzi, Liliana; Patti, Caterina; Gianni, Alessandro Massimo; Tarella, Corrado.
In: American Journal of Hematology, Vol. 88, No. 12, 12.2013, p. 1062-1067.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
AU - Rambaldi, Alessandro
AU - Boschini, Cristina
AU - Gritti, Giuseppe
AU - Delaini, Federica
AU - Oldani, Elena
AU - Rossi, Andrea
AU - Barbui, Anna Maria
AU - Caracciolo, Daniele
AU - Ladetto, Marco
AU - Gueli, Angela
AU - De Crescenzo, Alberto
AU - Passera, Roberto
AU - Devizzi, Liliana
AU - Patti, Caterina
AU - Gianni, Alessandro Massimo
AU - Tarella, Corrado
PY - 2013/12
Y1 - 2013/12
N2 - The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of
AB - The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B-cell lymphoma (DLBCL). We reviewed the outcome of 1,057 DLBCL patients followed from 1984 to 2012 at four centers. LMR was analyzed as a clinical biomarker by receiver-operating characteristic (ROC) analysis and Harrell's C-statistics. Patients were characterized by a median age of 61 years, International Prognostic Index (IPI) score of >2 in 39%, and were treated with a rituximab-containing chemotherapy in 66%. LMR proved strongly predictive for survival in patients treated with rituximab-based programs, but not in those receiving chemotherapy alone. Additionally, an LMR value of ≤2.6 (as determined by ROC analysis) was associated with a worst performance status, a higher lactate dehydrogenase (LDH) level, an advanced clinical stage, and a higher IPI score (P=0.000). In patients treated with rituximab-supplemented chemotherapy programs, an LMR value of
UR - http://www.scopus.com/inward/record.url?scp=84888067608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888067608&partnerID=8YFLogxK
U2 - 10.1002/ajh.23566
DO - 10.1002/ajh.23566
M3 - Article
C2 - 23940056
AN - SCOPUS:84888067608
VL - 88
SP - 1062
EP - 1067
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 12
ER -